SEC Form 6-K filed by Nymox Pharmaceutical Corporation

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the Month of July, 2023

Commission File Number: 001-12033

Bay & Deveaux Streets, Nassau, The Bahamas 

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒      Form 40-F ☐

On July 13, 2023, Nymox Pharmaceutical Corporation (the “Company”) issued a press release providing additional information concerning recent changes in the Company’s board of directors and management, as well as additional information regarding the Company’s conclusion that a potential transaction was not in the best interests of the Company and its shareholders. This press release is furnished as Exhibit 99.1 to this report on Form 6-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Act”), or otherwise subject to the liabilities of that section.

On July 18, 2023, the Company issued a press release announcing the issuances of several of its important U.S. patents for NYMOZARFEX™. This press release is furnished as Exhibit 99.2 to this report on Form 6-K and shall not be deemed to be “filed” for the purposes of Section 18 of the Act, or otherwise subject to the liabilities of that section.

EXHIBIT INDEX

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 25, 2023